Clinical Trial Detail

NCT ID NCT02205333
Title A Phase 1b/2 Safety and Tolerability of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies
Recruitment Terminated
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors MedImmune LLC
Indications

Advanced Solid Tumor

Therapies

Rituximab

MEDI6469

Tremelimumab

Durvalumab

Age Groups: adult

No variant requirements are available.